NASDAQ · CDIOW
Healthcare · Biotechnology
$0.01
Up+$0.00 (+20.41%)
Updated Nov 5, 2026, 9:34 AM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CDIOW
1M range · 17 trading sessions · Daily adjusted prices
Prices through Nov 4, 2026
CDIOW closed at $0.01 after 17 trading sessions, up 25.53% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 4, 2026 | $0.0118 | $0.0119 | $0.0118 | $0.0118 | 35.24K |
| Nov 3, 2026 | $0.012 | $0.012 | $0.0098 | $0.0098 | 7.1K |
| Nov 2, 2026 | $0.0098 | $0.0098 | $0.0098 | $0.0098 | 1.91K |
| Oct 30, 2026 | $0.0098 | $0.012 | $0.0098 | $0.0098 | 28.82K |
| Oct 29, 2026 | $0.0098 | $0.012 | $0.0098 | $0.0098 | 15.79K |
| Oct 28, 2026 | $0.0098 | $0.0098 | $0.0098 | $0.0098 | 2.52K |
| Oct 22, 2026 | $0.012 | $0.012 | $0.012 | $0.012 | 209 |
| Oct 21, 2026 | $0.0095 | $0.012 | $0.0094 | $0.012 | 32.29K |
| Oct 20, 2026 | $0.0123 | $0.0123 | $0.0123 | $0.0123 | 35.22K |
| Oct 19, 2026 | $0.0076 | $0.0123 | $0.0067 | $0.0123 | 66.92K |
| Oct 15, 2026 | $0.008 | $0.0088 | $0.0064 | $0.0064 | 31.73K |
| Oct 14, 2026 | $0.0077 | $0.0089 | $0.0076 | $0.0089 | 15.11K |
| Oct 13, 2026 | $0.0075 | $0.0092 | $0.0075 | $0.0092 | 14.99K |
| Oct 12, 2026 | $0.0074 | $0.0098 | $0.0074 | $0.0075 | 23.7K |
| Oct 9, 2026 | $0.011 | $0.011 | $0.0052 | $0.01 | 101.3K |
| Oct 8, 2026 | $0.011 | $0.0112 | $0.0092 | $0.0092 | 10.2K |
| Oct 7, 2026 | $0.0118 | $0.0118 | $0.0094 | $0.0094 | 2.3K |
The latest Smart Investors Daily articles mentioning CDIOW.
Company
Market Activity
Research & News
CDIOW research
Company profile and research snapshot.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
SeekingAlpha · Sep 18, 2026
Cardio Diagnostics Holdings, Inc. (CDIO) Shareholder/Analyst Call September 18, 2026 12:00 PM EDTCompany ParticipantsMeeshanthini Dogan - Co-Founder, CEO...
Yahoo · Aug 26, 2026
CHICAGO, August 26, 2026--Cardio Diagnostics has released a new edition of the company’s rural health report: The State of Rural Hospitals and Cardiovascular Care.
SeekingAlpha · Aug 20, 2026
Cardio Diagnostics Holdings, Inc. (CDIO) Discusses Precision Molecular Advances and AI for Cardiovascular Disease Detection and Strategic Growth Initiatives...
Yahoo · Aug 18, 2026
CHICAGO, August 18, 2026--Cardio Diagnostics launched its in-house, high-complexity CLIA-certified laboratory in Iowa City, Iowa.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CDIOW.
No results
No recent SID articles mention CDIOW.
